News

Sequenom said that these newly acquired rights expand the company’s existing, broad intellectual property (IP) portfolio of noninvasive prenatal diagnostic methods using fetal nucleic acids obtained from a

Peter Parker, president and CEO of Cequent, said: “When we started the Novartis program, we were evaluating eight targets simultaneously as potential therapeutics for inflammatory bowel disease. Our

In June 2008, the company changed its name to MDRNA based upon the company’s scientific and intellectual property position surrounding the R&D of RNA interference (RNAi) drug candidates.

The company anticipates that this research will lead to the selection of a drug candidate to treat trypanosomiasis initially in livestock followed by a human treatment for the

Bayer said that this decision marks the first approval for Xarelto worldwide. Bayer will start marketing the product immediately. The approval from Health Canada was based on data

According to Wright Medical, Biotape XM reinforcement matrix is the latest addition to the company’s biologics portfolio of technologies for foot and ankle surgery featuring Graftjacket regenerative tissue

In addition, the new company completed an E8 million financing in the form of Series A preferred stock. The participating institutions included Bankhaus Wolbern (Hamburg) and NRW Bank

According to the company, Sancuso is a transdermal system, or skin patch, that delivers granisetron, its active component and an established inhibitor of nausea and vomiting, through a

With the acquisition of the biotech company specialized in protein engineering, Bayer said that it is strengthening the research competence in biologicals of its pharmaceutical division, Bayer Schering